The FDA Outlook of Events Reporting after Ticagrelor or Clopidogrel in the PLATO Trial: Impact of Sponsor Censoring Dates, Drug Discontinuation, and Withdrawal of Consent

Publisher： Karger

E-ISSN： 1421-9751|120|3|169-171

ISSN： 0008-6312

Source： Cardiology, Vol.120, Iss.3, 2012-01, pp. : 169-171

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Gastrointestinal Adverse Events after Dual Antiplatelet Therapy: Clopidogrel Is Safer than Ticagrelor, but Prasugrel Data Are Lacking or Inconclusive

By  

Cardiology, Vol. 126, Iss. 1, 2013-07 ,pp. : 35-40

Karger

Access to resources Recommend Favorite

Exploring the Ticagrelor-Statin Interplay in the PLATO Trial

By  

Cardiology, Vol. 124, Iss. 2, 2013-02 ,pp. : 105-107

Karger

Access to resources Recommend Favorite

Withdrawal Symptoms after Selective Serotonin Reuptake Inhibitor Discontinuation: A Systematic Review

By  

Psychotherapy and Psychosomatics, Vol. 84, Iss. 2, 2015-02 ,pp. : 72-81

Karger

Access to resources Recommend Favorite

Ticagrelor FDA Approval Issues Revisited

By  

Cardiology, Vol. 122, Iss. 3, 2012-07 ,pp. : 144-147

Karger

Access to resources Recommend Favorite

Aspirin Dose and Ticagrelor Benefit in PLATO: Fact or Fiction?

By  

Cardiology, Vol. 117, Iss. 4, 2011-02 ,pp. : 280-283

Karger

Access to resources Recommend Favorite